Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364:937-952. Abstract
Crestor® PI. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021366s016lbl.pdf. Accessed March 19, 2017.
Roberts, WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol. 1997;80:106-107. Abstract
Stein E, Sprecher D, Allenby KS, et al. Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia. J Cardiovasc Pharmacol Ther. 1997;2:7-16. Abstract
Pravachol® PI 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019898s062lbl.pdf. Accessed March 19, 2017.
LaRosa JC, He J, Vuppituri S. Effect of Statins on Risk of Coronary Disease A Meta-analysis of Randomized Controlled Trials. JAMA. 1999;282:2340-2346. Abstract
Chin CW, Gao F, Le TT, et al. Lipid Goal Attainment and Prescription Behavior in Asian Patients with Acute Coronary Syndromes: Experience from a Tertiary Hospital. Clin Med Insights Cardiol. 2013;7:51-57. Abstract
Mc Kenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344-2353. Abstract
Ballantyne CM, Neutel J, Cropp A, et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol. 2015;115:1212-1221. Abstract
Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380:2007-2017. Abstract
ClinicalTrials.gov. NCT01764633. Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER). Available at: https://clinicaltrials.gov/ct2/show/NCT01764633. Accessed March 20, 2017.
ClinicalTrials.gov. NCT01663402. ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab. Available at: https://clinicaltrials.gov/ct2/show/NCT01663402. Accessed March 20, 2017.
ClinicalTrials.gov. NCT01975376. The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1). Available at: https://clinicaltrials.gov/ct2/show/NCT01975376. Accessed March 20, 2017.
ClinicalTrials.gov. NCT01975389. The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2). Available at: https://clinicaltrials.gov/ct2/show/NCT01975389. Accessed March 20, 2017.
Sabatine MS, Giugliano RP, Keech A, et al. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. Am Heart J. 2016;173:94-101. Abstract
Sabatine MS. Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER). Paper presented at: 66th Annual Meeting of the American College of Cardiology; March 2017; Washington, DC.
Sabatine MS, Giugliano RP, Keech AC, et al. N Engl J Med. 2017. doi: 10.1056/NEJMoa1615664. [Epub ahead of print]
Giugliano RP, Mach F, Zavitz K, et al. Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial. Clin Cardiol. 2017;40:59-65. Abstract
Giugliano RP. EBBINGHAUS: A Cognitive Study of Patients Enrolled in the FOURIER Trial. Paper presented at: 66th Annual Meeting of the American College of Cardiology; March 2017; Washington, DC.
Lipinski MJ, Benedetto U, Escarcega RO, et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J. 2016;37:536-645. Abstract
Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. New Engl J Med. 2017. doi: 10.1056/NEJMoa1701488. [Epub ahead of print]

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Stephen J. Nicholls, MBBS, PhD

Professor of Cardiology, University of Adelaide; Heart Health Theme Leader, SAHMRI Heart Foundation, South Australian Health & Medical Research Institute, Adelaide, South Australia, Australia

Disclosures

Disclosure: Stephen J. Nicholls, MBBS, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; CSL Behring; Merck & Co., Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Takeda
Received grants for clinical research from: Amgen Inc.; Anthera Pharmaceuticals; AstraZeneca; Cerenis Therapeutics; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Sanofi

Editor

Walid Amara, MD

Scientific Director, WebMD Global, LLC

Disclosures

Disclosure: Walid Amara, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BIOTRONIK; Served as a speaker or a member of a speakers bureau for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Pfizer Inc.; MSD, Novartis, MEDA, Boston Scientific; Medtronic, Inc.; Livanova; St. Jude Medical.

Content Reviewer

Robert Morris, PharmD

Associate CME Clinical Director

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed no relevant financial relationships.

High Risk Dyslipidemia Management in Asia Pacific

From Medscape Education

What's New With the Treatments of High-Risk Dyslipidemia?

Authors: Stephen J. Nicholls, MBBS, PhDFaculty and Disclosures

processing....

Posted: 25/3/2017

This educational activity is intended for an international audience of Asia-Pacific healthcare professionals, specifically cardiologists, diabetologists & endocrinologists, and primary-care physicians involved in the management of patients with high-risk dyslipidemia.

Upon completion of this activity, participants will:

Have increased knowledge regarding the:

Optimal management of patients with high-risk dyslipidemia
Impact of new therapies on the risk of CV events

Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the European Medicines Agency for use in Europe and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Faculty

Stephen J. Nicholls, MBBS, PhD

Editor

Walid Amara, MD

Content Reviewer

Robert Morris, PharmD

What's New With the Treatments of High-Risk Dyslipidemia?